

# **2022 U.S. Infectious Disease Testing Market-Growth Opportunities, Supplier Shares by Test, Segmentation Forecasts for 100 Respiratory, STD, Enteric, and other Virology, Bacteriology, Parasitology and Mycology Assays Performed in Hospitals, Commercial/Private Labs, POC Locations-Competitive Strategies and SWOT Analysis, Latest Technologies, Instrumentation Pipeline, Market Barriers and Risks**

<https://marketpublishers.com/r/27D033A55E46EN.html>

Date: November 2022

Pages: 0

Price: US\$ 3,850.00 (Single User License)

ID: 27D033A55E46EN

## **Abstracts**

This unique report from LeadingMarketResearch.com provides data and analysis not available from any other published source, including test volume and sales forecasts for 100 individual tests, and competitor strategies, as well as strategic analysis of major business opportunities emerging in the infectious disease testing market during the next five years.

The report is available by section, and can be customized to specific information needs and budget. The report examines key US market trends; reviews current and emerging assays; analyzes potential applications of innovative diagnostic technologies; forecasts volume and sales for over 100 infectious disease tests by assay, and market segment; provides test volume estimates by method (molecular, serology/immunodiagnosics, culture/microscopy); profiles leading players and potential market entrants; and suggests alternative business expansion strategies for suppliers.

### **Rationale**

This comprehensive report will assist diagnostics industry executives, as well as companies planning to diversify into the dynamic and rapidly expanding microbiology

testing market, in evaluating emerging opportunities and developing effective business strategies.

Microbiology testing is one of the most rapidly growing segments of the in vitro diagnostics industry, and the greatest challenge facing suppliers during this decade. Among the main driving forces is continuing spread of AIDS, which remains the world's major health threat and a key factor contributing to the rise of opportunistic infections; threat of bioterrorism; advances in molecular diagnostic technologies; and a wider availability of immunosuppressive drugs.

Although for some infections the etiology is still a mystery, while for others the causative microorganisms are present in minute concentrations long before the occurrence of first clinical symptoms, recent advances in genetic engineering and detection technologies are creating exciting opportunities for highly sensitive, specific and cost-effective products.

#### Opportunities and Strategic Recommendations

Emerging opportunities for new instrumentation, reagents kits, IT and other products with significant market appeal during the next five years.

Design criteria for decentralized testing products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

#### Infectious Diseases Analyzed in the Report

AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis, Campylobacter, Candida, Carbapenemase, Chancroid, Chlamydia, Clostridium, Coronavirus, Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus, Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale, Hantavirus, H. Pylori, Hepatitis, Herpes, Influenza, Legionella, Lyme Disease, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium, Mononucleosis, Mumps, Mycoplasma, Norovirus, HPV, Parvovirus, Pneumonia, Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus, Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci, Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.

## Market Segmentation Analysis

Sales and market shares of major suppliers by individual test.

Volume and sales forecasts for over 100 infectious disease assays by individual test and market segment:

Hospitals, Blood Banks, Commercial/Private Laboratories, Physicians Offices/Group Practices, Public Health Laboratories

Test volume estimates by method (molecular, serology/immunodiagnostics, culture/microscopy).

Review of the market dynamics, trends, structure, size, growth and major suppliers.

## Current and Emerging Products

In-depth examination of over 100 major diseases, including their etiology, current diagnostic tests, vaccines, drugs and market needs.

Review of major analyzers used for infectious disease testing, including their operating characteristics, features and selling prices.

## Technology Review

Assessment of molecular diagnostic, monoclonal antibody, immunoassay, and other technologies and their potential applications for infectious disease testing.

Global listings of companies developing or marketing infectious disease diagnostic products by individual test.

## Competitive Assessments

Strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new products in R&D.

## Contents

### INTRODUCTION

### WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

#### A. Major Infectious Disease Tests

##### 1. AIDS

- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs

##### 2. Adenovirus

- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- d. Adeno-Associated Viruses(AAV)

##### 3. Aeromonas

- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs

##### 4. Anthrax/Bacillus Anthracis

- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs

##### 5. Arboviruses

- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs

##### 6. Babesiosis

- a. Background

##### 7. Bacillary Epithelioid Angiomatosis (BEA) And Other Bartonella (Rochalimaea)

- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs

##### 8. Blastocystis Hominis

- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs

- 9. Brucella
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 10. Campylobacter
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 11. Candida
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 12. Chagas Disease
  - a. Background
- 13. Chancroid
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 14. Chlamydia
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 15. Clostridium Difficile
  - a. Background
  - b. Diagnostic Tests
  - c. Drugs and Vaccines
- 16. Coronaviruses
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 17. Coxsackieviruses
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 18. Creutzfeldt-Jakob's Disease
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines
- 19. Cryptosporidium Parvum

- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 20. Cyclospora Cayetanensis
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 21. Cytomegalovirus
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 22. Ebola Virus
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 23. E. Coli
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 24. EchoVirus
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 25. Encephalitis
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 26. Enteroviruses
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 27. Epstein-Barr Virus
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 28. Giardia Lamblia
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs

- 29. Gonorrhea
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 30. Granuloma Inguinale
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 31. Hantavirus
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 32. Helicobacter Pylori
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 33. Hepatitis
  - a. Background
  - b. Hepatitis A
  - c. Hepatitis B
  - d. Hepatitis C
  - e. Vaccines and Drugs
- 34. Herpes Simplex Virus
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 35. Human Herpes Virus-6 (HHV-6)
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 36. Influenza Viruses
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 37. Legionella
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 38. Lyme Disease



- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs
- 39. Lymphogranuloma Venereum (LGV)
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 40. Malaria
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 41. Measles (Rubeola)
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 42. Meningitis
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 43. Microsporidium
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 44. Mononucleosis
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 45. Mumps
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 46. Mycoplasma
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 47. Papillomaviruses
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs

- 48. Parvovirus B19
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 49. Pneumonia
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 50. Polyomaviruses
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 51. Pseudomonas Aeruginosa
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 52. Rabies
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 53. Respiratory Syncytial Virus (RSV)
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 54. RhinoViruses
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 55. RotaVirus (REOVIRUS)
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 56. Rubella(MEASLES)
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 57. Salmonellosis
  - a. Background
  - b. Diagnostic Tests

- c. Vaccines and Drugs
- 58. Septicemia
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 59. Shigellosis
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 60. Staphylococcus Aureus
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 61. Streptococci
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 62. Syphilis
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 63. Toxoplasmosis
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 64. Trichomonas Vaginalis
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 65. Tuberculosis
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 66. Vibrio
  - a. Background
  - b. Diagnostic Tests
  - c. Vaccines and Drugs
- 67. West Nile Virus
  - a. Background

- b. Diagnostic Tests
- c. Vaccines and Drugs

#### 68. Yersina

- a. Background
- b. Diagnostic Tests
- c. Vaccines and Drugs

B. Instrumentation Review of Leading Analyzers Marketed by Abbott, Beckman Coulter/Danaher, BioMerieux, Ortho-Clinical Diagnostics, Roche, Siemens, Tosoh, Wallac and Other Suppliers

#### C. Emerging Diagnostic Technologies

1. Molecular Diagnostics
2. Monoclonal Antibodies
3. Immunoassays
4. Differential Light Scattering
5. Information Technology
6. Artificial Intelligence
7. Liposomes
8. Flow Cytometry
9. Chromatography
10. Diagnostic Imaging
11. Gel Microdroplets
12. Other

### **U.S.**

- A. Executive Summary
- B. Business Environment
- C. Market Structure
- D. Market Size, Growth and Major Suppliers

### **MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES**

- A. Instrumentation
- B. Reagent Kits and Test Systems/Panels
- C. Computers, Software and Automation
- D. Auxiliary Products

### **DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS**

## **ALTERNATIVE MARKET PENETRATION STRATEGIES**

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies for Decentralized Testing Markets
  - 1. Marketing Approaches
  - 2. Product Complexity
  - 3. Customer Preference
  - 4. Established Suppliers
  - 5. Emerging Suppliers
  - 6. Major Types of Distributors
  - 7. Market Segmentation

## **POTENTIAL MARKET ENTRY BARRIERS AND RISKS**

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

## **COMPETITIVE ASSESSMENTS**

Abbott  
Agilent Technologies  
Applied Gene Technologies  
Arca Biopharma  
Beckman Coulter/Danaher  
Becton Dickinson  
Biokit  
bioMerieux  
Bio-Rad  
Decode Genetics  
Eiken Chemical  
Elitech Group  
Enzo Biochem

Exact Sciences  
Fujifilm Wako  
Fujirebio  
Grifols  
Hologic  
Illumina  
Leica Biosystems  
Li-Cor Biosciences  
Myriad Genetics  
OrthoQuidel  
PerkinElmer  
Proteome Sciences  
Qiagen  
Quest Diagnostics  
Roche  
Scienion  
Sequenom/LabCorp  
Shimadzu  
Siemens Healthineers  
Sierra Molecular  
Takara Bio  
Tecan Group  
Thermo Fisher

## I would like to order

Product name: 2022 U.S. Infectious Disease Testing Market-Growth Opportunities, Supplier Shares by Test, Segmentation Forecasts for 100 Respiratory, STD, Enteric, and other Virology, Bacteriology, Parasitology and Mycology Assays Performed in Hospitals, Commercial/Private Labs, POC Locations-Competitive Strategies and SWOT Analysis, Latest Technologies, Instrumentation Pipeline, Market Barriers and Risks

Product link: <https://marketpublishers.com/r/27D033A55E46EN.html>

Price: US\$ 3,850.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/27D033A55E46EN.html>